This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Giuseppe Ciaramella, Ph.D.
Chief Scientific Officer at BeamTherapeutics


Dr Giuseppe Ciaramella is the Chief Scientific Officer of Beam Therapeutics. Ciaramella has more than 20 years of drug discovery experience at Moderna, AstraZeneca, Boehringer Ingelheim, Pfizer and Merck. Throughout his career he has held several leadership roles, with a particular focus in the fields of antivirals, immunology and biotherapeutics. Prior to joining Beam Therapeutics, Dr Ciaramella was the CSO of the Infectious Diseases division of Moderna Therapeutics, where he was instrumental in generating some of the first mRNA vaccines to be dosed in humans, several of which are progressing through clinical studies. At Boehringer Ingelheim, he served as Vice President and Head of Collaborative Research where he had responsibility for external R&D and was a member of the Research Leadership Team. Prior to Boehringer Ingelheim, he spent 14 years at Pfizer in the UK where he held several Discovery leadership positions, including head of Biotherapeutics, head of Antivirals and head of Lead Discovery. He has contributed to several clinical candidates, both small molecule and biologics and to the anti-HIV drug Maraviroc (Selzentry TM), which won the USA Prix Galien for Best Pharmaceutical in 2008. He is a member of the Infectious Diseases Society of America (IDSA) and of the American Society of Gene Therapy (ASGT). Dr. Ciaramella holds a PhD in Biochemistry and Molecular Biology from University College London.

Agenda Sessions

  • Keynote Introduction by Session Chair and KEYNOTE PRESENTATION with Live Q&A - Base Editing: A Next Generation Gene Editing Technology and Its Application to Cure Serious Genetic Diseases